Pfizer ‘respectfully requests’ the FDA to reconsider phytosterol rule change
Pfizer has joined a growing number of companies calling on the FDA to rethink a controversial December 2010 proposed rule that would ban cardiovascular disease risk reduction claims on supplements containing non-esterified phytosterols.